Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c

Cue Biopharma, Inc. (NASDAQ: CUE) reported Q2 EPS of ($24.14), $20.54 worse than the analyst estimate of ($3.60). Revenue for the quarter came in at $7.88 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Cue Biopharma, Inc. (CUE) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Albany International ends strategic review, keeps Salt Lake City facility
• Biosenta signs MOU with Dynamic Facility Services for disinfectant pilot